cardioprotectant

cardioprotectant

 [kahr″de-o-pro-tek´tant]
1. counteracting cardiotoxic effects.
2. an agent that so acts.

cardioprotectant

/car·dio·pro·tec·tant/ (-pro-tek´tant) counteracting cardiotoxicity, or an agent that so acts.

cardioprotectant

[kär′dē·ōprōtek′tant]
1 adj, counteracting cardiotoxic effects.
2 n, an agent, such as a beta-blocker, that so acts.
References in periodicals archive ?
There was no significant difference in five-year event-free survival for patients receiving dexrazoxane/doxorubicin when compared to those receiving doxorubicin alone, suggesting that the cardioprotectant agent did not negatively impact anti-leukemic outcomes.
Protykin[R] is a phytoestrogen, cardioprotectant and antioxidant for women, which is derived from the root of Polygonum cuspidatum.
The Company's lead drug is a novel cardioprotectant called MC-1.
552 cardioprotectant may include coronary artery bypass graft surgery, aortic valve replacement, angioplasty, non-cardiac surgery in high-risk patients, unstable angina, acute myocardial infarction, thrombolytic therapy, stroke and other CNS injury and organ transplantation.
FUSA) today announced the signing of a joint development agreement (JDA) to develop adenosine as a cardioprotectant in the settings of coronary artery bypass graft (CABG) surgery and acute myocardial infarction (MI).
While certain of these AGP molecules potentiate immune responses, others, including Corixa's RC-552 cardioprotectant candidate, induce tissue-protective enzymes such as nitric oxide synthase.
Therefore, the present interest in testing adenosine's potential as a cardioprotectant, in association with thrombolytic and PTCA therapy of acute myocardial infarction, and during bypass surgery is validated by the data presented in Orlando.
Obtaining the right to use intravenous adenosine as a cardioprotectant in combination with thrombolytic therapy, balloon angioplasty and coronary bypass surgery
In the event that MRE markets an adenosine-containing cardioprotectant product, FHI will receive an 8% royalty on MRE's net sales.
During the remainder of 1998 we anticipate announcing our plans and next steps for moving forward with the development of intravenous adenosine as a cardioprotectant and the potential use of an adenosine A2a-agonist as a selective vasodilator.
In Europe, Chiron Therapeutics also markets Cardioxane, a cardioprotectant used as an adjunct to doxorubicin therapy for cancer.
Supplemental d-ribose is an excellent candidate as a cardioprotectant, because it serves multiple targets.